{"product_id":"inmb-pestle-analysis","title":"(INMB) INmune Bio, Inc. PESTLE Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to Market Insight Starts Here\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis INmune Bio, Inc. PESTLE Analysis shows how political, economic, social, technological, legal, and environmental forces may affect the company; the page includes a real preview\/sample so you can judge style and depth before buying. Purchase the full version to receive the complete, ready-to-use company-specific analysis for strategy, investing, or research.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003ePolitical factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eU.S.-based biotech, Boca Raton, Florida\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc. faces U.S. federal health policy risk because the FDA oversees trial design, safety, and approval, while NIH funding helps shape biotech research demand. Congress also affects reimbursement rules that can drive commercial uptake after approval. Florida adds state-level business and tax exposure, with the corporate income tax at 5.5% in 2025, while the federal corporate rate stays 21%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 active core programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc.’s 3 core programs — INKmune, INB03, and XPro1595 — make FDA and other public-sector reviews a major political risk. Oncology and Alzheimer’s assets draw extra scrutiny because they target severe, high-need diseases. If regulators grant breakthrough or fast-track status, development can move faster, but only when the data are strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Political-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINmune Bio's clinical-stage model depends on stable U.S. FDA policy, because one protocol change can add months and millions to trial costs. The FDA's FY2024 budget was about $7.2 billion, showing how tightly biotech is tied to regulation. Strong U.S. support for biomedicine also matters: NIH funding was about $48.6 billion, which helps fund sites, investigators, and patient access.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003e2015 founding year\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFounded in 2015, INmune Bio, Inc. is still only about 10-11 years old, so policy changes can hit its runway harder than they would a mature drug maker. Early-stage biotech firms depend more on public funding and grant support than diversified pharmaceutical groups, so shifts in NIH or FDA policy can move financing and trial timing fast. Favorable innovation rules can also help keep partnering and capital formation open.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2015 founding keeps policy risk high.\u003c\/li\u003e\n\u003cli\u003ePublic funding matters more than scale.\u003c\/li\u003e\n\u003cli\u003ePro-innovation policy supports cash access.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eLicensing ties with 4 institutions and firms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eINmune Bio, Inc.'s licensing ties with Xencor, Immune Ventures, the University of Pittsburgh, and University College London create cross-border policy risk, especially where U.S. and U.K. rules on research, IP, and exports differ.\u003c\/p\u003e\n\u003cp\u003ePolitics matter because trade controls and collaboration rules can affect data sharing, lab work, and deal terms; the U.S. and U.K. remain core hubs for biotech R\u0026amp;D, with U.K. R\u0026amp;D spend at £46.3 billion in 2023.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFour-party licensing adds policy complexity.\u003c\/li\u003e\n\u003cli\u003eU.S.-U.K. stability supports continuity.\u003c\/li\u003e\n\u003cli\u003eExport controls can slow collaboration.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eINmune Bio Faces Fast-Shifting FDA, NIH, and Reimbursement Risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePolitical risk for INmune Bio, Inc. is centered on FDA trial rules, NIH funding, and reimbursement policy, because all three can shift timelines and cash needs fast. Florida’s 5.5% corporate income tax in 2025 and the U.S. 21% federal rate also affect cost of capital. Cross-border licensing adds extra exposure to U.S.-U.K. research and IP rules.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eLatest data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA FY2024 budget\u003c\/td\u003e\n\u003ctd\u003eAbout $7.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNIH FY2024 funding\u003c\/td\u003e\n\u003ctd\u003eAbout $48.6B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFlorida corporate tax 2025\u003c\/td\u003e\n\u003ctd\u003e5.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. federal rate\u003c\/td\u003e\n\u003ctd\u003e21%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eMaps the external forces shaping INmune Bio, Inc. across Political, Economic, Social, Technological, Environmental, and Legal factors.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eA concise INmune Bio PESTLE snapshot that simplifies external risks and market factors for fast, clear decision-making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise bibliography linking INmune Bio claims to primary sources (regulatory filings, clinical data, industry reports) to speed due diligence and verify assumptions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEconomic factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage, pre-commercial revenue risk\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINmune Bio has 0 approved products and no commercial sales, so its economics still depend on trial results, partnerships, and capital raises. That makes dilution risk and milestone timing key value drivers. In a weak biotech funding market, higher financing costs can slow programs and pressure valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e3 development programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWith 3 development programs, INmune Bio spreads spending across trials, research, and manufacturing readiness, so each added indication lifts clinical and capital needs. If one program slows, management may have to rephase spend to protect cash and keep the rest moving.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Economic-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology and Alzheimer’s market size\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eOncology is a huge spend pool: the global cancer drug market was about $292 billion in 2024, while Alzheimer’s therapy sales are still early but rising after the first disease-modifying launches. That scale matters for INmune Bio, Inc. because blood cancer, solid tumor, ovarian carcinoma, MDS, and Alzheimer’s can support premium pricing if efficacy and safety are clear. The tradeoff is long, costly development, with oncology Phase 3 programs often taking 6-8 years and costing hundreds of millions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eBiotech capital markets sensitivity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiotech capital markets stay rate-sensitive for INmune Bio, Inc.; with policy rates still near 4% in 2025, higher discount rates raise the cost of funding trials and push down small-cap biotech valuations.\u003c\/p\u003e\n\u003cp\u003eIn weak risk-on periods, investors demand bigger discounts, so any new equity can dilute existing holders more sharply.\u003c\/p\u003e\n\u003cp\u003eThat matters for a clinical-stage company with limited operating cash flow and a need to fund R\u0026amp;D before revenue arrives.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigher rates lift capital costs.\u003c\/li\u003e\n\u003cli\u003eLow liquidity can delay financings.\u003c\/li\u003e\n\u003cli\u003eWeak sentiment increases dilution.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePartnership and licensing economics\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eFor INmune Bio, Inc., licensing can cut internal R\u0026amp;D burn by sharing assets and know-how, while also creating upfront, milestone, and royalty income if a program advances. In biotech, royalties are often structured in the low-single-digit to low-teens range, so one deal can matter more than a small equity raise. For a small biotech, that makes partnerships a key non-dilutive funding source.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLower R\u0026amp;D spend\u003c\/li\u003e\n\u003cli\u003eUpfront cash possible\u003c\/li\u003e\n\u003cli\u003eMilestones lift upside\u003c\/li\u003e\n\u003cli\u003eRoyalties can fund growth\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eINmune Bio’s High-Risk, High-Reward Cancer Bet\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc. stays cash-hungry: no approved products, 3 active programs, and funding tied to trial readouts and capital markets. In 2025, rates near 4% kept equity funding expensive, while the global cancer drug market was about $292 billion in 2024, supporting premium upside if INmune Bio, Inc. proves efficacy.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eData\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved products\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDevelopment programs\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePolicy rates\u003c\/td\u003e\n\u003ctd\u003eNear 4% in 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal cancer drug market\u003c\/td\u003e\n\u003ctd\u003e$292 billion in 2024\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eINmune Bio, Inc. PESTLE Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the exact INmune Bio, Inc. PESTLE Analysis you’ll receive after purchase—fully formatted, professionally structured, and ready to use for strategic or investment decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eSociological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlzheimer’s disease focus in aging populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAging populations are expanding Alzheimer’s demand: WHO says 55 million people live with dementia worldwide, and that could reach 78 million by 2030 and 139 million by 2050; Alzheimer’s causes 60% to 70% of cases. This rising burden keeps neurodegeneration front and center for older adults and caregivers. INmune Bio’s XPro1595 fits that need, and societal pressure for true disease-modifying results can speed uptake if outcomes are strong.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eWomen with relapsed or refractory ovarian carcinoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eWomen with relapsed or refractory ovarian carcinoma face very limited options, since about 20,890 U.S. cases and 12,730 deaths were expected in 2025. This high unmet need can lift INKmune trial awareness, because patients and families often seek new options fast. Strong advocacy for women’s cancer also helps enrollment, funding, and clinician interest in INmune Bio, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Social-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-risk myelodysplastic syndrome patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eHigh-risk myelodysplastic syndrome is a serious blood cancer, with U.S. incidence around 4 to 5 cases per 100,000 people a year and a median age at diagnosis near 76. It often needs specialized oncology care because survival can be short without effective treatment. That burden supports demand for novel immunotherapies, but adoption depends on clear safety and quality-of-life data.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eNeed for diverse clinical trial recruitment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBiotech trials face closer scrutiny on who gets enrolled, and that matters for INmune Bio, Inc. Black adults are 13.7% and Hispanic adults 19.1% of the U.S. population, so narrow enrollment can weaken how well trial results reflect real patients. Diverse recruitment can also speed enrollment, reduce dropout risk, and improve trust in INmune Bio, Inc. programs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDiverse trial pools improve credibility.\u003c\/li\u003e\n\u003cli\u003eBroader enrollment can speed recruitment.\u003c\/li\u003e\n\u003cli\u003eBetter mix can raise public trust.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eImmunotherapy awareness in cancer care\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePublic awareness of immunotherapy has risen as the FDA has cleared 100+ immunotherapy indications, making immune-based care more familiar to patients and oncologists. When standard therapy fails, that familiarity can lift willingness to try INmune Bio, Inc.'s innate-immune approach and support stronger trial enrollment. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMore awareness lowers fear of new treatments.\u003c\/li\u003e\n\u003cli\u003ePhysicians can consider it earlier after failure.\u003c\/li\u003e\n\u003cli\u003eTrial recruitment can improve with social acceptance.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAging Demand Powers INmune Bio’s Opportunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc. benefits from aging-driven demand: WHO counts 55 million people with dementia, rising to 78 million by 2030. High unmet need in Alzheimer’s, ovarian cancer, and MDS keeps patients, caregivers, and advocates focused on new options. Diverse trial enrollment also matters because broad representation builds trust and makes results more usable.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003eKey data\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDementia burden\u003c\/td\u003e\n\u003ctd\u003e55M now; 78M by 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOvarian cancer\u003c\/td\u003e\n\u003ctd\u003e20,890 cases; 12,730 deaths\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eU.S. population mix\u003c\/td\u003e\n\u003ctd\u003e13.7% Black; 19.1% Hispanic\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eTechnological factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInnate immune system platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINmune Bio’s platform targets the innate immune system, not just adaptive immunity, which gives it a distinct angle in oncology and inflammation. That matters because innate immune biology can shape tumor signaling and chronic inflammatory pathways earlier in the disease process. Platform credibility still depends on reproducible biomarker shifts and clinical response data from its 2025-2026 trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eINKmune, INB03, XPro1595 pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc.'s INKmune, INB03, and XPro1595 programs span oncology, hematology, inflammation, and neurodegeneration, so the company is not tied to one market. That diversification can spread scientific risk, but it also raises execution risk because each program needs its own assays, clinical endpoints, and CMC (chemistry, manufacturing, and controls) plan. For a small biotech, managing 3 distinct platforms at once can stretch capital and slow timelines.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Technological-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical-stage translational science\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical-stage translational science is a key risk for INmune Bio, Inc. Moving from lab data to human proof needs strong biomarker choice, dose finding, and mechanism validation; poor translation is a major reason drugs fail, with about 90% of candidates missing approval in clinical development. Weak results can slow proof of concept and make follow-on capital harder and more costly to raise.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAcademic licensing inputs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eINmune Bio, Inc.'s licenses from the University of Pittsburgh and University College London point to external scientific IP and research know-how that can speed drug development if the transfer is tight. Academic-origin assets can cut early R\u0026amp;D time, but they also need strong tech transfer and reproducibility across labs. In 2025, INmune Bio, Inc. reported no product revenue and kept its work tied to R\u0026amp;D execution, so licensed science matters a lot.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExternal IP can speed discovery\u003c\/li\u003e\n\u003cli\u003eReproducibility risk stays real\u003c\/li\u003e\n\u003cli\u003eTransfer quality drives value\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eAdvanced immunotherapy development\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced immunotherapy development is becoming more data-heavy, with genomics, immune profiling, and analytics used to select patients and track response. For INmune Bio, Inc., this can sharpen trial design and cut late-stage failure risk; in biotech, Phase 3 failure rates still run near 50% to 65%, so better technical tools matter.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrecision patient selection improves trial fit\u003c\/li\u003e\n\u003cli\u003eImmune monitoring can flag response early\u003c\/li\u003e\n\u003cli\u003eData tools may reduce costly study failures\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eINmune Bio’s 2025-2026 test: can its platform deliver repeatable clinical data?\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eINmune Bio’s tech edge is its innate-immune platform, but the key test in 2025-2026 is whether INKmune, INB03, and XPro1595 keep showing reproducible biomarker and response data across trials.\u003c\/p\u003e\n\u003cp\u003eWith 3 programs across oncology, inflammation, and neurodegeneration, the Company needs strong assay design, patient selection, and CMC control; in small biotech, that complexity can slow execution and raise burn.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eTech factor\u003c\/th\u003e\n\u003cth\u003e2025-2026 signal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlatforms\u003c\/td\u003e\n\u003ctd\u003e3 programs\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e0 product revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCore risk\u003c\/td\u003e\n\u003ctd\u003eClinical translation\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eLegal factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFDA clinical trial oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc.’s U.S. programs must follow FDA IND rules, including the 30-day review window and ongoing safety reporting under 21 CFR Part 312. Any protocol deviation or serious adverse event can trigger FDA questions, trial pauses, or extra review. For a clinical-stage biotech, tight compliance is not optional; it is what keeps the pipeline moving.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing agreements with 4 partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc. depends on 4 partner licenses, so it must meet IP, milestone, and royalty terms tied to each deal. These contracts can limit where and how each asset is used, including field-of-use and commercialization rights. If ownership or sublicensing is disputed, the value of the licensed programs can drop fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Legal-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatent protection for novel immunotherapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc.’s value in immunotherapy depends on enforceable IP, because U.S. patents run 20 years from filing and biologics can get 12 years of data exclusivity. Strong patent coverage can protect pricing power and improve partnering terms. If key claims are weak or near expiry, each program’s long-term economics can fall fast.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eHuman subject and ethics compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eINmune Bio, Inc. faces tight human-subject rules: informed consent, IRB\/ethics review, and rapid adverse-event reporting are mandatory in every trial. Alzheimer’s and oncology studies add extra scrutiny because older adults and seriously ill patients can be more vulnerable, so delays or consent gaps can trigger study holds and hurt trust.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eConsent must be clear and documented.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eEthics review can delay trial starts.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eSerious adverse events need fast reporting.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eFailures can pause studies and damage reputation.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003ePublic company disclosure duties\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAs a listed biotech, INmune Bio, Inc. must file SEC reports on time and disclose material trial, financing, and risk updates under Exchange Act rules. In 2025\/2026, that means 10-K, 10-Q, and 8-K disclosures must be precise, because misleading forward-looking statements or clinical data can trigger SEC scrutiny and shareholder claims. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eTimely SEC filings are mandatory.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eTrial and financing news must be material and accurate.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eMisleading guidance raises legal exposure.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eINmune Bio Faces FDA, IP, and SEC Compliance Risks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc. must keep FDA IND trials compliant under 21 CFR Part 312, with 30-day review and fast SAE reporting. Its 4 partner licenses add IP, royalty, and field-use risk, while patents and 12-year biologics exclusivity protect value. As a listed biotech, it must file 10-K, 10-Q, and 8-K on time.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eLegal area\u003c\/th\u003e\n\u003cth\u003eKey number\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eFDA IND\u003c\/td\u003e\n\u003ctd\u003e30 days\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics exclusivity\u003c\/td\u003e\n\u003ctd\u003e12 years\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eEnvironmental factors\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBoca Raton, Florida location\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBoca Raton, Florida leaves INmune Bio, Inc. exposed to hurricanes, floods, and storm outages; Florida saw two major hurricane hits in 2024, including Helene and Milton. Severe weather can delay office work, sample handling, and vendor deliveries, which is risky for time-sensitive biotech trials. Strong business continuity plans matter when even short disruptions can slow study operations.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLaboratory waste and biosafety\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc. must control chemical, biological, and sharps waste because lab disposal can cost 2-10x more than обычный municipal waste. Safe containment lowers spill, exposure, and permit risk, and it protects nearby communities. Strong biosafety controls also cut the chance of trial delays and reputational damage.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/PESTLE-Content-Enviromental-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCold-chain and temperature control\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eClinical materials for INmune Bio, Inc. often need 2°C to 8°C control, and some biologics face tighter limits. WHO has said about 25% of vaccines are wasted each year, with weak temperature control a major cause, so excursions can wipe out product and delay studies. Cold-chain failures also raise shipping, rework, and disposal costs, making temperature control a quality and environmental issue.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSmall physical footprint, high R\u0026amp;D intensity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eINmune Bio, Inc. has a small physical footprint because clinical-stage biotech work is mostly R\u0026amp;D, not large-scale manufacturing. Outsourced labs and trial sites still add indirect emissions, so vendor choices can shape the company’s ESG score. In 2025, this means the main environmental lever is supply-chain control, not factory efficiency.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSmall in-house footprint\u003c\/li\u003e\n\u003cli\u003eIndirect impact via CROs\u003c\/li\u003e\n\u003cli\u003eVendor ESG matters\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eSupply chain resilience for trial materials\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eEnvironmental events can delay couriers, suppliers, and contract research sites, and that matters when INmune Bio, Inc. depends on timed sample shipping and specialty reagents. Many clinical materials must stay at 2-8°C, while dry ice shipments sit near -78.5°C, so even short transit breaks can spoil trials.\u003c\/p\u003e\n\u003cp\u003eStrong backup logistics, dual sourcing, and local buffer stock help protect study continuity and cut waste. This is important because global air cargo still moves over 50 million tonnes a year, but weather, strikes, and route closures can hit small trial networks fast.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eUse backup couriers and lanes\u003c\/li\u003e\n\u003cli\u003eHold buffer stock near sites\u003c\/li\u003e\n\u003cli\u003eTrack temperature in real time\u003c\/li\u003e\n\u003cli\u003ePre-qualify alternate labs and vendors\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStorms and Cold-Chain Risks Threaten INmune Bio Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eINmune Bio, Inc. faces climate risk from South Florida storms, which can disrupt labs, couriers, and cold-chain shipments. 2025 also kept temperature control critical: WHO says about 25% of vaccines are wasted each year, often from weak storage. That makes backup logistics and real-time monitoring essential.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eFactor\u003c\/th\u003e\n\u003cth\u003e2025-2026 relevance\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStorms\u003c\/td\u003e\n\u003ctd\u003eFlorida hurricane outages\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold chain\u003c\/td\u003e\n\u003ctd\u003e2-8°C or spoilage risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWaste\u003c\/td\u003e\n\u003ctd\u003eBio waste costs 2-10x more\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234497929481,"sku":"inmb-pestle-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/inmb-pestle-analysis.webp?v=1785722022","url":"https:\/\/dcfanalyst.com\/products\/inmb-pestle-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}